Do all patients with breast cancer benefit from neoadjuvant chemotherapy?

Lee, Kyoung Eun

doi:10.3904/kjim.2020.535

Cited by 5 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy is one of the main treatments for breast cancer, usually in the form of a combination of drugs to maximize tumor eradication without poisoning any host system [107]. The antitumor mechanism of chemotherapeutic drugs is generally believed to bind to the DNA of tumor cells and thereby prevent DNA replication.…”

Section: Pdt Combined With Chemotherapymentioning

confidence: 99%

Metal Nanoparticles for Photodynamic Therapy: A Potential Treatment for Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignant tumor in women worldwide, which seriously threatens women’s physical and mental health. In recent years, photodynamic therapy (PDT) has shown significant advantages in cancer treatment. PDT involves activating photosensitizers with appropriate wavelengths of light, producing transient levels of reactive oxygen species (ROS). Compared with free photosensitizers, the use of nanoparticles in PDT shows great advantages in terms of solubility, early degradation, and biodistribution, as well as more effective intercellular penetration and targeted cancer cell uptake. Under the current circumstances, researchers have made promising efforts to develop nanocarrier photosensitizers. Reasonably designed photosensitizer (PS) nanoparticles can be achieved through non-covalent (self-aggregation, interfacial deposition, interfacial polymerization or core-shell embedding and physical adsorption) or covalent (chemical immobilization or coupling) processes and accumulate in certain tumors through passive and/or active targeting. These PS loading methods provide chemical and physical stability to the PS payload. Among nanoparticles, metal nanoparticles have the advantages of high stability, adjustable size, optical properties, and easy surface functionalization, making them more biocompatible in biological applications. In this review, we summarize the current development and application status of photodynamic therapy for breast cancer, especially the latest developments in the application of metal nanocarriers in breast cancer PDT, and highlight some of the recent synergistic therapies, hopefully providing an accessible overview of the current knowledge that may act as a basis for new ideas or systematic evaluations of already promising results.

show abstract

Section: Pdt Combined With Chemotherapymentioning

confidence: 99%

Metal Nanoparticles for Photodynamic Therapy: A Potential Treatment for Breast Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This difference was attributed to the HER2+ subgroup because about 2/3 or 3/4 HER2+ subgroup patients showed a higher proportion in the δL1 < δL2 or δV1 < δV2 groups, respectively, than the δL1 ≥ δL2 and δV1 ≥ δV2 groups, consequently resulting in a higher pCR rate in these HER2+ subgroups ( Table 2 ). It is reasonable that targeted therapy can enhance the anti-tumor effect on HER2+ breast cancer ( 17 , 18 ).…”

Section: Discussionmentioning

confidence: 99%

Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response

Zhang²,

Wang³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Neoadjuvant systemic therapy (NST) is widely applied in breast cancer treatment, but individuals respond differently to the same NST regimen. It is unclear which patients should adjust their NST regimen and what such an adjustment should be, especially for patients with radiologically partial response (PR). This study aimed to identify a quantitative efficacy evaluation index to evaluate the therapeutic effect of NST. 164 patients were enrolled in this study received four cycles of epirubicin and cyclophosphamide (EC), followed by four cycles of taxanes with trastuzumab [T(H)], if needed. Of patients with a volume change rate of EC treatment (δV1) below 0.80, more than half benefited from subsequent T(H) treatment compared with EC treatment. Importantly, for δV1 of 0.80 and higher, patients’ subsequent T(H) treatment was not as efficient as previous EC treatment and they have a lower pathological complete response (pCR) rate. Across all patients, nanoparticle albumin-bound paclitaxel had a numerically higher pCR rate over other taxanes in patients with triple-negative breast cancer. This study showed that the volume change rate is better than the diameter change rate in monitoring the therapeutic effect of NST. Furthermore, δV1 is a good quantitative efficacy evaluation index to distinguish patients resistant to EC treatment and predict the pCR rate and guide the adjustment of individualized NST regimens.

show abstract

“…This difference was attributed to the HER2+ subgroup because about 2/3 or 3/4 HER2+ subgroup patients showed a higher proportion in the δL1 < δL2 or δV1 < δV2 groups, respectively, than the δL1 ≥ δL2 and δV1 ≥ δV2 groups, consequently resulting in a higher pCR rate in these HER2+ subgroups (Table 2). It is reasonable that targeted therapy can enhance the anti-tumor effect on HER2+ breast cancer [16,17].…”

Section: Discussionmentioning

confidence: 99%

Volume change rate before and after neoadjuvant systemic therapy of breast cancer is a good quantitative efficacy evaluation index to predict pathological complete response

Zhang

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Neoadjuvant systemic therapy (NST) is increasingly and widely applied in breast cancer treatment, but individuals respond differently to the same NST regimen. It is unclear which patients should adjust their NST regimen and what such an adjustment should be, especially for patients with radiologically partial response (PR). This study aimed to identify a quantitative efficacy evaluation index to evaluate the therapeutic effect of NST. Methods: Patients with locally advanced and inoperable breast cancer received four cycles of epirubicin and cyclophosphamide (EC), followed by four cycles of taxanes with trastuzumab [T(H)], if needed. Retrospectively, 164 patients were enrolled in this study. Results: Of patients with a volume change rate of EC treatment (δV1) below 0.80, more than half benefited from subsequent T(H) treatment. Importantly, for δV1 of 0.80 and higher, fewer patients benefited from subsequent T(H) treatment, with those not benefiting having a lower pathological complete response (pCR) rate. Across all patients, nanoparticle albumin-bound paclitaxel had a numerically higher pCR rate over other taxanes in patients with triple-negative breast cancer. Conclusions: This study showed that the volume change rate is better than the diameter change rate in monitoring the therapeutic effect of NST. Furthermore, δV1 is a good quantitative efficacy evaluation index to distinguish patients resistant to EC treatment and predict the pCR rate. It can also guide the adjustment of individualized NST regimens.

show abstract

Do all patients with breast cancer benefit from neoadjuvant chemotherapy?

Cited by 5 publications

References 8 publications

Metal Nanoparticles for Photodynamic Therapy: A Potential Treatment for Breast Cancer

Metal Nanoparticles for Photodynamic Therapy: A Potential Treatment for Breast Cancer

Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response

Volume change rate before and after neoadjuvant systemic therapy of breast cancer is a good quantitative efficacy evaluation index to predict pathological complete response

Contact Info

Product

Resources

About